You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for pep2-EVKI
pep2-EVKI is an inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluA2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).
Technical Data for pep2-EVKI
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References for pep2-EVKI
References are publications that support the biological activity of the product.
Collingridge and Isaac (2003) Functional roles of protein interactions with AMPA and kainate receptors. Neurosci.Res. 47 3 PMID: 12941441
Daw et al (2000) PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron 28 873 PMID: 11163273
Hanley et al (2002) Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression. Neuron 34 53 PMID: 11931741
Li et al (1999) AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses. Nat.Neurosci. 2 972 PMID: 10526335
View Related Products by Product Action
Keywords: pep2-EVKI, pep2-EVKI supplier, Peptide, inhibitors, inhibits, GluR2, subunit, binding, PICK1, Glutamate, AMPA, Receptors, iGluR, Ionotropic, GluA2, 1599, Tocris Bioscience
2 Citations for pep2-EVKI
Citations are publications that use Tocris products. Selected citations for pep2-EVKI include:
Yao et al (2008) PKM ζ maintains late long-term potentiation by N-ethylmaleimide-sensitive factor/GluR2-dependent trafficking of postsynaptic AMPA receptors. Proc Natl Acad Sci U S A 28 7820 PMID: 18667614
Dickinson et al (2009) A novel mechanism of hippocampal LTD involving muscarinic receptor-triggered interactions between AMPARs, GRIP and liprin-alpha. Mol Brain 2 18 PMID: 19534762
Reviews for pep2-EVKI
There are currently no reviews for this product. Be the first to review pep2-EVKI and earn rewards!
Have you used pep2-EVKI?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.